Thanks to all of the CCTG sites who participated, making Canada one of the top 10 accruing countries globally and responsible for a quarter of the North American patients enrolled on the trial. As of December 2019 the final international accruals were 518 patients (target: 500) with 29 enrolled patients from Canada.
The Canadian Cancer Society (CCS) is excited to launch the CCS Emerging Scholar Award program, aimed at establishing and advancing promising early career scientists and clinician scientists from across Canada with a focused commitment to undertaking cancer research. Through the CCS Emerging Scholar Award program, early career investigators will develop their cancer research programs in Canada and pursue important scientific advances of the highest quality and potential for impact.
Published: January 22, 2020
A recently published article in the American Journal of Clinical Pathology about the submission of tumour blocks for NCTN trials is the result of work done by the Group Banking Committee of the US NCI which CCTG is a charter member.(Publication)
REC.3 (NCT02761057), A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005],Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET), has been closed to accrual after completion of target accrual. Treatment and follow-up of accrued patients will continue according to the protocol.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.
MAC7 (NCT00075764) trial: Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer has been permenantly closed.